Pulmonary Department Oncology Unit, G Papanikolaou General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Future Oncol. 2013 Sep;9(9):1307-13. doi: 10.2217/fon.13.111.
Lung cancer therapies during the last decade have focused on targeting the genome of cancer cells, and novel routes for administering lung cancer therapies have been investigated for decades. Aerosol therapies for several systematic diseases and systemic infections were introduced into the market a decade ago. One of the main issues of aerosol therapies has been the ability to investigate the deposition of a drug compound throughout the systematic circulation and lymph node circulation. Until now, none of the published studies have efficiently shown the deposition of a chemotherapy pharmaceutical within the lymph node tissue. In our current work we present, for the first time, with the novel CytoViva(®) (AL, USA) technique, the deposition of cisplatin aerosol therapy in surgically resected stage II lymph nodes from lung cancer patients. Finally, we present the distribution of cisplatin in correlation with the cisplatin concentration in different lymph stations and comment on the possible mechanisms of distribution.
在过去的十年中，肺癌治疗的重点集中在针对癌细胞的基因组上，并且已经研究了数十年的新型肺癌治疗途径。 大约十年前，已经将几种系统性疾病和全身感染的气溶胶疗法引入市场。 气溶胶疗法的主要问题之一是能够研究药物化合物在整个全身循环和淋巴结循环中的沉积。 到目前为止，尚无发表的研究有效地显示出在淋巴结组织中沉积化疗药物。 在我们目前的工作中，我们首次使用新型 CytoViva ® （AL，美国）技术，展示了肺癌患者手术切除的 II 期淋巴结中顺铂气雾剂治疗的沉积。 最后，我们展示了顺铂在不同淋巴结站中的分布与顺铂浓度的相关性，并讨论了可能的分布机制。
